Asterion Raises £355k Funding to Progress Novel Therapies for Hormone Related Diseases

16-May-2006

Biofusion plc announced that its portfolio company Asterion Ltd, the Sheffield-based drug development company has raised £355k to progress its novel therapies for hormone-related diseases. Biofusion led the round, investing £250k. The White Rose Technology Seedcorn Fund ("WRTSF"), the venture capital fund owned by the Universities of Leeds, Sheffield and York, invested £105k. Following the investment, Biofusion's shareholding in Asterion will be 38.01%.

Asterion is developing specialised hormones (cytokines) which are implicated in a range of diseases including diabetes and cancer as well as obesity, growth and inflammatory disorders. Asterion has developed and patented a range of technologies to produce cytokine agonists, which mimic or complement the action of a target hormone, and cytokine antagonists which reduce or inhibit the hormone action. Drugs based on these technologies have the potential to lower dose requirements, increase stability and slow clearance from the bloodstream, all leading to potentially improved performance.

Asterion has established a research programme with a major multi-national pharmaceutical company to develop growth hormone antagonists and agonists. The new investment will enable Asterion's to expand its research and technologies to further target hormones. These include established pharmaceuticals such as erythropoietin as well as drug targets of the future including the obesity hormone, leptin.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase

Heptares granted patents covering stabilised receptor technology in Europe and Japan - Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery

Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity

Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics

Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics

Amarin corporation Appoints Colin W. Stewart as President and Chief Executive Officer

Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”

Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration

A sprinkle of platinum nanoparticles onto graphene makes brain probes more sensitive

A sprinkle of platinum nanoparticles onto graphene makes brain probes more sensitive

Merck and Washington University working on diagnostics and treatment of malnutrition - Genome editing to be used in intestinal bacteria research

Biophage Pharma announces sale of Immunotox Labs Division to Validapro BioSciences Inc

Rescue for Sardines and Anchovies: Produce DHA through biotechnology using microalgae

Rescue for Sardines and Anchovies: Produce DHA through biotechnology using microalgae